Cash: As of March 31, 2025, Cellectis had $246 million in consolidated cash, cash equivalents, restricted cash and fixed-term deposits classified as current-financial assets. The Company believes its ...

Six posters presented at the American Association for Cancer Research (AACR) annual meetingAppointment of Dr. Sabeen Mekan as Senior Vice President, Clinical DevelopmentReported $321.6 million in cash ...

At some point in life, everyone has a moment when they realize they have made a terrible financial mistake. Whether it’s buying a car, a home, or a disappointing vacation, there can and will be an ...

In April 2025, our partner Jazz announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of ...

Discover Zymeworks' Q1 2025 earnings insights: strong revenue growth, pipeline advancements, and financial stability through 2027.

He’s developed images and visuals for North Texas musical giants Leon Bridges and Post Malone in addition to iconic brands, ...

BioAtla Inc (BCAB) showcases significant advancements in clinical trials while navigating financial hurdles and seeking strategic partnerships.

Students at Plains Elementary School recently showcased their creativity in the second annual Beautification Days art contest. Children from kindergarten through sixth grade were invited to design ...

CAMBRIDGE, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading ...

Pivotal Phase 3 LUCIDITY trial of avexitide, a potential first-in-class GLP-1 receptor antagonist with FDA breakthrough therapy designation, underway in post-bariatric hypoglycemia (PBH); completion ...

Data cutoff date for Phase 2b NAVIGATE trial efficacy reached on April 30, 2025; top-line data readout expected in late June ...